Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection

Detalles Bibliográficos
Autores principales: Kemmner, Stephan, Guba, Markus O., Schönermarck, Ulf, Stangl, Manfred, Fischereder, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Nephrology. Published by Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270808/
https://www.ncbi.nlm.nih.gov/pubmed/32505466
http://dx.doi.org/10.1016/j.kint.2020.05.024
_version_ 1783541964996608000
author Kemmner, Stephan
Guba, Markus O.
Schönermarck, Ulf
Stangl, Manfred
Fischereder, Michael
author_facet Kemmner, Stephan
Guba, Markus O.
Schönermarck, Ulf
Stangl, Manfred
Fischereder, Michael
author_sort Kemmner, Stephan
collection PubMed
description
format Online
Article
Text
id pubmed-7270808
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher International Society of Nephrology. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-72708082020-06-05 Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection Kemmner, Stephan Guba, Markus O. Schönermarck, Ulf Stangl, Manfred Fischereder, Michael Kidney Int Article International Society of Nephrology. Published by Elsevier Inc. 2020-08 2020-06-04 /pmc/articles/PMC7270808/ /pubmed/32505466 http://dx.doi.org/10.1016/j.kint.2020.05.024 Text en © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Kemmner, Stephan
Guba, Markus O.
Schönermarck, Ulf
Stangl, Manfred
Fischereder, Michael
Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection
title Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection
title_full Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection
title_fullStr Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection
title_full_unstemmed Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection
title_short Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection
title_sort cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with covid-19 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270808/
https://www.ncbi.nlm.nih.gov/pubmed/32505466
http://dx.doi.org/10.1016/j.kint.2020.05.024
work_keys_str_mv AT kemmnerstephan cyclosporineasapreferredcalcineurininhibitorinrenalallograftrecipientswithcovid19infection
AT gubamarkuso cyclosporineasapreferredcalcineurininhibitorinrenalallograftrecipientswithcovid19infection
AT schonermarckulf cyclosporineasapreferredcalcineurininhibitorinrenalallograftrecipientswithcovid19infection
AT stanglmanfred cyclosporineasapreferredcalcineurininhibitorinrenalallograftrecipientswithcovid19infection
AT fischeredermichael cyclosporineasapreferredcalcineurininhibitorinrenalallograftrecipientswithcovid19infection

Ejemplares similares